# A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

> **NCT00001446** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 64 (—)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00001446
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-09
- **Primary completion:** —
- **Final completion:** 2001-07
- **Target enrollment:** 64 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001446, "A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*